Microbiome and Rectal Cancer

Running, not enrolling · Not applicable

Conditions studied: Rectal Cancer, Locally Advanced Malignant Neoplasm

In brief

The purpose of our study is to determine if an association exists between the microbiome of those with rectal adenocarcinoma who are complete pathologic responders and those who have a partial or no response to neoadjuvant therapy.

Key facts

Study ID

NCT04223102

Run by

University of South Florida

People needed

40

Starts

2020-02-18

Expected to finish

2027-06-01

Last updated by the study team

2023-08-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years old
• Locally Advanced Rectal Adenocarcinoma (T3)
• Standard 5FU based chemoradiation
• Total Neoadjuvant Therapy per OPRA protocol guidelines

You may not qualify if…

• Age < 18 years
• Stage I or Stage IV rectal adenocarcinoma
• Rectal cancer other than adenocarcinoma
• Genetically associated cancer (HNPCC, FAP etc.) or highly suspicious for genetically associated cancer
• Prior history of rectal adenocarcinoma (i.e. recurrent colorectal adenocarcinoma)

Where it is running

• Tampa General Hospital — Tampa, Florida, United States
• University of South Florida - South Tampa Campus — Tampa, Florida, United States
• University of South Florida — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.